With the isolation of human embryonic stem cells (hESCs) in 1998 came the realization of a long-sought aspiration for an unlimited source of human tissue. The difficulty of differentiating ESCs to pure, clinically exploitable cell populations to treat genetic and degenerative diseases is being solved in part with the help of genetically modified cell lines. With progress in genome editing and somatic cell nuclear transfer, it is theoretically possible to obtain genetically repaired isogenic cells. Moreover, the prospect of being able to select, isolate and expand a single cell to a vast population of cells could achieve a unique level of quality control, until now unattainable in the field of gene therapy. Most of the tools necessary to develop these strategies already exist in the mouse ESC system. We review here the advances accomplished in those fields and present some possible applications to hESC research.
Introduction
Human embryonic stem cells (hESCs) are cell lines derived from the inner cell mass of human blastocysts. 1 More than 120 hESCs lines have been derived throughout the world 2 that all share the main characteristics of mouse embryonic stem cells (mESCs): self-renewal, clonogenicity and pluripotentiality. This last trait may provide a unique and unlimited source of cells for cell replacement therapy, and the two former make these cells particularly amenable to genetic engineering. When injected into immunodeficient hosts, hESCs form teratomas, which are complex masses composed of cells belonging to the three germ layers: endoderm, ectoderm and mesoderm. When cultured in vitro in the absence of growth factors, hESCs form embryoid bodies (EBs), masses comprised of cells of multiple lineages. Because EB-mediated differentiation is spontaneous and seemingly random, the full potential of hESCs must be harnessed through well-defined differentiation protocols to enrich specific cell lineages of clinical interest.
Many different methods of directing the differentiation of ESCs toward particular lineages have been studied. Most rely on the combined use of soluble molecules, defined conditioned media and coculture with feeder cell lines. Such conditions have been described to drive the differentiation of hESC to neurons, 3 definitive endoderm, 4 cardiomyocytes, 5 hematopoietic cells, 6,7 hepatocytes, 8 osteogenic cells 9 and germ cells. 10 Other parameters such as physical stimuli, free radicals or gas-controlled environments that mimic the early embryo are also contemplated to influence the differentiation of ES cells. 11 Manipulating the genome of hESCs could provide a key element to potential clinical applications of hESCs. First, the ectopic expression of intracellular factors during in vitro culture could supply an additional stimulus to control the differentiation of hESCs. Second, hESCs, when transplanted to animal models, can be rejected or form teratomas. This would obviously present a risk in clinical applications, and genetic elements could be used to increase the safety of employing these cells in vivo. Third, hESCs present an unparalleled opportunity to fully benefit from the advantages of site-specific homologous recombination (HR).
hESCs can be genetically modified without losing their pluripotency
The genomic plasticity of murine ESCs (mESCs) has greatly contributed to biological research these past 25 years. With the advent of hESCs, the great amount of experience acquired in generating transgenic mESCs can be used in the manipulation of the genome of hESCs in order to achieve disease models and clinically relevant applications. We will address here the different gene transfer techniques available, and their possible use in the hESC setting.
Transient transfection
The most frequent method to generate transiently or stably DNA-transfected mESC is electroporation. However, unlike mESC, hESC are very sensitive to electric-pulse-mediated DNA transfer. Other commonly used transfection methods in hESCs are cationic lipids (Lipofectamine), non-liposomal cationic vectors (Fugene), polyethylenimines (Exgen 500). Modified protocols were recently formulated to increase the transfection efficiency of hESC, either using electroporation, 12 nucleofection 13, 14 or silica microspheres. 15 Gene expression after transient DNA transfection in hESC is limited to 48-120 h, and has limited value in terms of applications, unless the aim is to express genes very early during the in vitro differentiation process. For instance, transient transfection of OCT4-silencing RNA interference (RNAi) in hESCs rapidly upregulates endoderm and neural-associated markers, 16, 17 and transient downregulation of Nanog in hESCs increased markers for trophectoderm and extraembryonic endodermal lineages. 18 Other strategies to introduce transiently expressed genes could also be employed. Most of these alternative gene transfer techniques, including microinjection, adenovirus (Ad), 19 adeno-associated virus (AAV), herpesvirus or non-integrative retroviruses 20 have, however, not been assessed in hESCs, with the exception of Ad5 and AAV2. 21 Of note, the use of autonomously replicating extrachromosomal elements, such as plasmids containing an origin of replication, has recently been assessed in the context of hESCs. 22 This strategy allows the introduction of large fragments (100-300 kb) of genomic DNA to hESC, whereas avoiding DNA integration. The expression of an episomally expressed green fluorescent protein (GFP) transgene can be in these conditions maintained for several months, and was reversible upon withdrawal of antibiotic selection.
Random transgenesis
The traditional approach of gene therapy has mostly been aimed at inserting a new copy of a gene under the control of an exogenous promoter. This approach, also known as gene augmentation, has been used with success in preclinical settings, but has met many obstacles when used to treat patients with an integrating retrovirus. The most serious risk presented by the approach of random gene augmentation is insertional mutagenesis. DNA insertion at random sites in the genome of ESCs occurs by spontaneous integration upon transfection of DNA. DNA integration frequency is reported to be about one cell per 10 2 -10 4 transfected cells for mammalian genomes. Eiges et al. 23 have reported that despite inefficient DNA transfection rates in hESC, random integration occurred in about one in 10 5 H9 hESCs after transfection with polyethylenimines. This work represents the first description of genetic engineering of hESCs, by stably transfecting the gene coding for GFP under the control of the REX1 promoter, a murine gene expressed in undifferentiated cells. For this, hESCs were transfected with a plasmid containing the sequence of Rex1HGFP as well as a neomycinresistance gene, and were subsequently selected in the presence of neomycin. This model also provided the first in vitro tool for reporting the undifferentiated state of hESCs and demonstrated that the genome of hESCs could be modified without losing their inherent properties of self-renewal and pluripotency.
The rates of spontaneous DNA integration are altogether too low to be practical, and require positive selection. As hESCs are expandable from single clones, 24 they provide an ideal base for such strategies and many transgenic hESC lines containing selective transgenes have been generated this way (see Table in Supplementary Information). However, the potential immunogenicity of the exogenous transgenes used for selection may hamper their use in a clinical setting. 25 
Viral integration
The principal barriers to gene augmentation are (1) the transduction rates of target cells; (2) the risks associated with random integration; and (3) gene silencing which may occur during the life of the cell. The development of replication-deficient lentiviral vectors may address some of these issues.
Viral-mediated infection provides a rapid and efficient means to transfer genetic material to ESCs; however, transgenes are subject to progressive transcriptional gene silencing resulting in variable to complete loss of expression. This is particularly true for replicationdeficient retrovirus-based vectors when used in the 26 The development of replication-deficient, self-inactivating, pseudotyped lentiviruses used in gene therapy provided a way to introduce a gene in the hES genome with higher efficiency. 27 Lentiviral vectors have also been described to minimize the occurrence of silencing compared to retroviruses, but it is not clear whether this results from overall higher copy numbers in the target cells or from inherent features of lentivirus-based vectors, such as the distribution of the integration sites in the genome. 28 Further modification of the lentiviral constructs with novel insulator elements that block chromatin silencing, to ensure a stabilized expression of transgenes throughout ESC differentiation has been particularly encouraging. Ma et al., 29 for instance, showed that incorporation of two such elements (a scaffold attachment region from the human interferon-b gene and a chromatin insulator from the chicken b-globin locus) to the lentiviral vector backbone increased and stabilized the average level of transgene expression in hESCs.
The broad host range of infection of lentiviruses, their capacity to infect non-dividing cells and the relative ease of introducing specific promoters in their coding sequence have rendered them the virus of choice for infecting hES cells, particularly with RNAi constructs. 30 In most cases, strong viral or cellular promoters, such as the human phosphoglycerate kinase 1 promoter, the human elongation factor 1a promoter, or the composite CAG (consisting of the cytomegalovirus immediate-early enhancer, the chicken b-actin promoter and rabbit b-globin polyadenylation signal) promoter, are employed to drive efficient transgene expression in hESC. A further advantage of lentiviruses is the possible incorporation of cell-specific 31 or drug-inducible 32, 33 promoters to control transgene expression in the progeny of the infected cells. Other highly efficient replication-deficient vectors, such as feline immunodeficiency-based viruses, equine anemia-based viruses or visna-based viruses (reviewed by Romano 34 ) remain, however, untested in the hESC setting.
Site-specific integration
Transcriptional gene silencing has been partly bypassed in the field of mESC transgenesis by targeting the genome of ESCs by HR to a highly open, constitutively active gene locus of the genome: the ROSA26 locus. The ROSA26 locus was first described as a gene-trapped locus on chromosome 6, from which a transgene was shown to be expressed in all the cells of the mouse. It is, for the moment, still a matter of speculation if a region with such properties exists in the human genome, but the potential to target predefined loci of the genome would greatly enhance the expression stability of transgenic hESC lines.
Other than poor or irregular expression owing to the epigenetic nature of the integration site, another problem may arise from the random nature of viral transgene integration: the expression of an essential endogenous gene may be disrupted or improperly activated by the proximity of the transgene or its promoter. For instance, following retroviral infection, transactivation of the LMO2 gene has been observed after retroviral ex vivo gene therapy, leading to uncontrolled T-cell proliferation. 35 In this respect, working with ESCs, which are highly self-renewing and clonable, may greatly improve the safety of gene augmentation. One could imagine, for instance, isolating virally transduced ESC clones at the single-cell level, and assessing the viral insertion sites before usage ( Figure 1a ). Another way to address the risk of insertional mutagenesis is to develop methods for site-directed insertion of DNA sequences. Several systems have been designed to insert DNA sequences into predetermined artificial or natural genome sequences, thus achieving targeted insertion of foreign DNA into mammalian genomes. For instance, several integrative and excision pathways, such as Cre-lox or l-integrase, have been used efficiently to modify the genome of mESC. Three such integrases have been compared in hESCs: Cre, gd resolvase and l-integrase. In this episomal assay, efficient Cre-and l-mediated sitespecific recombination, and less efficient gd recombinasemediated recombination has been reported. 15 In a recent study, Cre-mediated recombination was achieved in hESC, targeting a randomly DNA-integrated construct. 36 Towards the aim of modifying the genome of hESCs, Cre recombinase could be used to remove marker genes by flanking them with lox sites, and l-integrase could provide a system to specifically target DNA insertion into user-determined attachment sites. These precise genome editing tools are especially valuable to gene therapy when used in the context of clonogenic hESCs. Indeed, several groups have demonstrated that hESCs are clonable at the single-cell level, albeit with a low frequency (o5%). 24 Improved single-cell cloning techniques will provide the unique opportunity to subclone and expand hESC at each step of the gene transfer procedure, thereby enabling the generation of homogeneous populations of quality controlled hESC lines (Figure 1a ).
HR in hESCs
For inherited single-gene disorders, gene repair via HR between an exogenous DNA matrix and chromosomal DNA would represent an ideal alternative to random integration to avoid the serious risks of gene transactivation, disruption or silencing. This strategy, also known as 'genome editing' would provide, in the case of genetic diseases, the only way to obtain isogenic, fully competent cells for cell therapy.
HR consists in exchanging DNA strands of identical or almost identical sequences between a donor DNA strand and a chromosomal site. Preclinical applications of HR have been fairly unsuccessful: because HR usually requires a long ex vivo culture and a high number of starting cells to be efficient, it is incompatible with the maintenance of the fragile undifferentiated state of most somatic stem cells, such as hematopoietic stem cells. HR between a transfected DNA sequence and its chromosomal target in mESCs is infrequent (about 10 À5 to 10 À8 events per transfected cell), and current applications of HR usually rely on positive selection of clones containing targeted sequences and negative selection to remove clones with random integration events. This 'positivenegative' selection process is ideally suited for clonogenic, self-renewing cells such as ESCs, which allow for very rare events, such as HR-mediated mutations, to be selected and expanded to a whole cell population. HR in ESCs is now a routinely used method to generate mouse disease models and other transgenic animals.
Gene transfer into ESCs F Yates and GQ Daley HR has not been as extensively employed in hESCs, and to date only three HR-targeted hESC lines exist. This is partly due to the major difficulties encountered in transfecting DNA into hESCs. In a first demonstration of a knockout strategy in this system, Zwaka and Thomson 12 developed a hESC model of Lesch-Nyhan disease by introducing a neomycin-resistance cassette by HR into the hypoxanthine phosphoribosyl transferase (HPRT1) gene. The frequency of HR was 1/10 5 cells, only 50 times lower than the reported frequency of non-HR. 12 It has been suggested that physical transfection of DNA sequences results in higher HR rates than chemical transfection methods. Indeed, lipid-based transfection agents yielded lower frequencies of HR of HPRT1 gene in hESCs. 37 Several strategies have been proposed to address the issue of low frequencies of gene targeting, aimed either at improving the transfection level, or at modifying the nature of the correcting DNA template. For instance, alternative transfection methods such as Ad-based 19 or microinjection have been used. Other methods, aimed at improving the overall rate of HR, have been assessed in somatic cells and should be assessed in the hESC setting, such as small fragment homologous replacement, 38 or triplex-forming oligonucleotides. 39 A series of recent developments in the field of HR may have a profound impact on site-specific genome editing of hESCs. It was shown that a double strand break generated at a target site could considerably improve the rates of HR. Customized, site-specific restriction endonucleases can be generated in a elegant system that couples customized zinc-finger domains specific for the IL2Rgc gene to the nonspecific DNA cleavage domain of the FokI restriction enzyme. 40 In this setting, not only is HR targeted to a specific, predetermined genomic site, but in this system more than 18% of the somatic cells treated bore one recombined allele, and 7% two alleles, even without selection. These remarkable results, addressing both problems of site-specificity and low recombination rates, allow for the first time HR to be considered in a therapeutic setting. Toward this aim, the authors described that 5% of transfected primary CD4+ T cells bore recombined alleles using the same technique. It is unclear if these results could be obtained with hESCs, particularly when targeting unexpressed loci of the genome. The advent of these new technologies may increase the rate a of HR to levels sufficient to avoid use of positive selection.
Gene therapy could be used in the context of somatic cell nuclear transfer Somatic cell nuclear transfer (SCNT) consists in generating an embryo by transferring the nucleus of a somatic cell to an oocyte, thereby reprograming the cell to a pluripotent status. SCNT has been employed successfully to derive ESCs from different species. 41 This technique offers for the first time the prospect of obtaining isogenic, human leukocyte antigen (HLA)-compatible, patient-specific hESCs. However, deriving ESCs from cloned embryos remains challenging in the human setting. Rare occurrence of human blastocysts obtained from SCNT was recently reported, 42 Gene transfer into ESCs F Yates and GQ Daley date there have been no reports of derivation of hESCs by SCNT. It is at this time unclear how efficiently such a strategy could be used to derive patient-specific hESC lines. Moreover, these results do not address the contentious issues linked with oocyte donation. 44 Alternative strategies are being investigated to reprogram somatic cells to a pluripotent state, including research for novel sources of oocytes, 10 somatic cell reprogramming through cell fusion 45 and novel sources of pluripotent stem cells, such as spermatogonial stem cells. 46 In the context of autologous patient-derived hESC, gene repair or genetic modification could be performed in a somatic cell before reprogramming, or in the patientspecific hESCs after derivation. However, the selfrenewal and clonogenic capacities as well as the genomic stability of undifferentiated hESCs mark them as preferred candidates for such genetic modifications (Figure 2) .
The proof of concept of such a strategy was performed by Rideout et al. 47 in a mouse model. Immunodeficient RAG2 À/À ESCs were treated by HR to repair one defective allele of the RAG2 gene. This was followed by an in vitro step to differentiate these ESCs to hematopoietic progenitors. Finally, these cells were transplanted to RAG2 À/À mice, partially restoring their lymphoid system. 47 Many steps remain to be refined to apply such a protocol in a therapeutic setting. Mainly, protocols for efficient, pure and safe hESC differentiation toward cell lineages of clinical relevance should be developed. In this respect, gene transfer can also play an important role, by directing the differentiation of ESC and by providing safer and more efficient ESC-derived therapy strategies.
Differentiation of hESCs through ectopic gene expression has been challenging
Mouse models of in vitro differentiation have provided evidence that ectopic gene expression in ESCs can greatly affect their fate in vitro. For example, gene augmentation with hNoggin, a glycoprotein known to act as a neuronal inducer and antagonist for bone morphogenetic proteins, drives rapid differentiation into a primitive neuronal phenotype. 48 In another system, transient expression of Cdx4 for 2 days followed by ectopic expression of HOXB4 in vitro in differentiating mESCs enhances multilineage engraftment of mESC-derived hematopoietic stem cells. 49 These models provide an insight into the complex processes taking place during in vitro differentiation. Applying these protocols to hESCs, however, may be more challenging, as significant differences between the murine and the human models of ESC differentiation have been noted. For instance, no specification toward neural lineages was observed after the stable ectopic expression of hNoggin in differentiated hESCs. 50 Another example is the ectopic expression of HOXB4, which has been reported by several independent groups to support the proliferation of engraftable hematopoietic progenitors in mESCs, 51 but not as robustly in hESCs. 52, 53 Although hESCs have a stable and significant proliferative capacity, this may not be true of hESC-derived cells. Some evidence has suggested, for instance, that hESC-derived hematopoietic progenitors and keratinocytes 53, 54 have much lower proliferative potential than their somatic counterparts. In the latter case, gene 
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Figure 2 Schematic for combined stem cell and gene therapy. Several steps can be prospectively identified for the treatment of genetic diseases by hESC and HR. A sample of a patient's cells (step 1) is taken to provide the nucleus necessary for SCNT or reprogramming (step 2). The embryo created is then cultured up to the blastocyst stage before hESC can be isolated from the inner cell mass and expanded (step 4). The next step involves gene repair of the patient's genetic defect by genome editing techniques, such as HR (step 5). Corrected hESC, which are isogenic to the patient, can then be selected or isolated clonally (see Figure 1) , expanded and differentiated to the cell type required (steps 6 and 7).
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transfer of the hTERT gene was not sufficient to restore the self-renewal capacity of the hESC-derived keratinocytes, but these cells were successfully immortalized by transduction of the E6E7 gene of the human papillomavirus 16 virus. Gene transfer could thus represent a critical tool to ensure the functional nature and control the quantity of hESC-derived cells.
Purification of differentiated cells
One of the main problems encountered after in vitro differentiation of ESCs is the heterogeneous nature of the populations obtained. Methods for inducing the cell types needed to model or treat particular diseases are currently being defined and optimized by a number of groups, but obtaining highly pure cells is key to improving efficacy and safety.
Differentiated cells obtained from ESCs can be isolated by cell-surface markers in order to obtain purified fractions of functional cells. In addition, purifying cells can avoid complications due to the potential contamination of the graft with residual undifferentiated ESCs. For instance, in a study by Burt et al., 55 mESC-derived engraftable hematopoietic progenitors were shown to express c-kit
+ cell-surface markers. The incidence of teratomas at the site of injection occurred only when whole, unsorted, cell populations were transplanted to irradiated mice, and not when fractionated c-kit + CD45 + were used. However, in some cases cell-surface markers are unavailable or not specific enough to select for highly enriched cells of interest. In this case, genetic reporter ESC lines expressing fluorescent proteins, such as GFP or yellow fluorescent protein, or cell-surface antigens such as CD4, placed under the control of lineage-specific promoters, can be used to track and purify these cells. Such genetically modified ESCs can be obtained either by stable transfection or by HR. These constructions have been used in mouse models to track cells in vivo, and can be used in vitro to characterize the best differentiation conditions and select for specific lineages.
This approach has been successfully used in the mouse model for a number of different cell fates. For example, Sox1 is a very early marker of neuroectoderm differentiation in the mouse embryo. The GFP fluorescent reporter protein was introduced by HR in one allele of the Sox1 endogenous gene, which enabled researchers to monitor the emergence of neuronal cells during in vitro culture. 56 A novel system for selective cell culture has been developed in mESCs by engineering the expression of a selectable gene driven by a lineage-specific promoter. This 'cell-trap' system restricts the culture to cells expressing a particular gene. Using this strategy, production and high enrichment of cardiomyocytes extracted from differentiating mESCs have been achieved with the myosin heavy-chain promoter controlling the expression of the gene coding for neomycin resistance, with cultures composed of more than 70% cardiomyocytes. 57 Cell-type-specific fluorescent reporters have been introduced in hESCs. The first models to be developed using this strategy were aimed at characterizing the undifferentiated state of hESCs. In a knock-in cell-trap strategy, one allele of POU5F1 (Oct4) was replaced by the coding sequence of a fluorescent reporter gene (GFP) coexpressed with a selection gene (neomycin resistance). 12 This system allowed both for the evaluation of the undifferentiated state of individual cells by fluorescence, and for the purification of undifferentiated ESCs from a mixed, partially differentiated cell population. In another study, a reporter gene (GFP) regulated by a hepatocyte-specific promoter, albumin, was introduced by stable transfection in hESCs. By sorting the fluorescent cells after in vitro differentiation, a homogenous, cell-type-specific population of hESC-derived cells was isolated for the first time. 58 Cell-trap and gene reporting techniques could greatly increase the yield of differentiated cells obtained from ESC differentiation, and sustain highly pure fractions of cells for cell therapy. This system relies, however, on the cell specificity of a single gene, which in some cases may prove too simplistic.
Gene transfer can provide safer ESC-based therapeutic strategies
Several complications could arise from using hESCs in a clinical setting, most notably teratoma formation upon engraftment, or rejection of allogenic hESCs. Strategies can be developed to improve the safety of potential hESC treatments, taking advantage of the plasticity of the hESC genome.
Teratoma formation
One of the hallmarks of ESCs is their pluripotency, which is reflected by their ability to form teratomas in vivo. Teratoma formation can hinder the therapeutic applications of ES-derived cells. For instance, ES-derived insulin-staining cells could only transiently reverse the hyperglycemia of diabetic mice before failing owing to teratoma formation. 59 Better characterization can be achieved and purification of differentiated cells before utilization in vivo must be achieved to avoid teratoma formation. Genetic modification itself may also provide a supplemental safety strategy. Schuldiner et al. 60 have described an original transgenic hESC system capable of reversing teratoma formation. By introducing a constitutively expressed herpes simplex virus thymidine kinase (HSV-TK) gene in the hESC genome, teratomas could be eliminated in vivo upon administration of ganciclovir. This strategy, which would require the reversal of the whole graft, relies on the complete lack of transgene silencing and an avoidance of transgene immunogenicity. It, however, offers an insight into the types of protective strategies made available when ingenuity is applied to genetically modified cells. Indeed, one could imagine combining cell-trap strategies and negative selection to devise a negative cell-trap system to eliminate all undifferentiated cells before transplantation (Figure 1b) . In this case, a negative selection gene, such as HSV-TK or caspase-2, 61 is placed under the control of a dual doxycycline-dependent Oct4 promoter. Cells could be treated at the end of the differentiation period with doxycycline to selectively eliminate all contaminating residual undifferentiated cells before transplantation. Lentiviral vectors have been described with similar systems, such as a HSV-TK gene driven by the promoter of the hTERT gene to allow post-therapeutic deletion of tumorigenic cells. 62 Gene transfer into ESCs F Yates and GQ Daley
Rejection of allogenic hESCs
ESCs and their derivatives, as any allogenic cells, may be rejected by the host's immune system after transplantation. To circumvent this problem, several strategies are conceivable. First, deriving isogenic, patient-specific hESC lines by somatic cell reprogramming or nuclear transfer; second, the creation of a bank of HLA-typed hESC, from which an adequate match could be selected; 63 and third, by modifying the genome of the target cell to avoid the risk of rejection.
The immune status of ESCs is a controversial issue. In some situations, such as myocardial injection, it has been shown that mESCs can trigger important allogenic immune reactions. 64, 65 However, cell-surface molecules or soluble factors secreted endogenously by ESCs and their progeny seem to modulate the immune response toward them. For example, rat or mouse ES-derived hematopoietic cells can survive engraftment in a xenogenic or fully mismatched environment without immunosuppression. 55, 66, 67 This property may be due to the embryonic nature of ESCs, and seems to be conserved in hESCs. Li et al. 68 have shown that hESCs and their derivatives can evade both in vivo xenogenic and in vitro allogeneic immune responses despite normal levels of MHCI. It was later unequivocally confirmed that hES and hES-derived cells can in some cases evade allogenic immune responses 69 based on a careful study performed in a NOD/SCID-based chimeric mouse-human model.
Immunomodulatory strategies to achieve tolerance of transplanted cells may play an important role in potential ESC therapies. One could propose, for example, to genetically alter the class I HLA locus to prevent rejection. This approach may, however, be very complex, owing to the extent of the regions to target. Other strategies could be used to decrease a possible specific allogenic reaction against transplanted hESCs, such as gene transfer-based inhibition of T-cell co-stimulatory molecules by ectopic expression of the CTLA4-Ig imunosuppressor gene. 70 Alternatively, the downregulation of class I HLA has been described in hESCs by RNAi against b 2 -microglobulin. 71 The immunogenicity of these cells was, however, not assessed. The issue of hESC rejection needs to be more systematically addressed before envisaging hESC therapies.
Prospects
hESCs represent an ideal tool to investigate the first steps of ontogeny, to model genetic diseases and perhaps in the long term to provide cells for tissue replacement therapy. However, the ethical precautions necessarily associated with the necessity to destroy an early, 4-to 5-day-old human embryo to obtain new lines of hESCs remain an obstacle to a more widespread study and utilization of this model system. Several alternatives have been proposed to obtaining hESC-like cells to overcome the ethical hurdles posed by the destruction of a human embryo: (1) nuclear reprogramming could be achieved by cell fusion; 45 (2) a single blastomere could potentially be excised from a living embryo and be used to derive a new ESC line; 72 or (3) non-embryonic sources of ESC-like cells, such as testes, could be identified.
Research on hESC, supported by the tools developed in the field of gene therapy, will be essential towards developing potential future cell therapy-based treatments for conditions for which there is no steady source of compatible cellular material. Already, a wide range of acquired or congenital hematopoietic and metabolic diseases are treatable by hematopoietic stem cell transplantation, such as primary immunodeficiencies, sicklecell anemia or acute myeloid leukemia. Experimental cell therapy-based treatments are also under way for a variety of auto-immune diseases (e.g., pancreatic islet transplantation for diabetes, myelinating cells transplantation for multiple sclerosis), and cell transplants have been suggested to treat spinal cord injuries, myocardial infarction or Parkinson's disease. The common feature for all these therapies is the poor resource and low numbers of cells available, often necessitating partially mismatched engraftments, thus mitigating the outcome of these procedures. hESC-derived cells could provide safe and abundant treatments for these pathologies.
Conclusion
In recent years, safety concerns raised by the mutagenic potential of gene transfer have highlighted the advantages of cell therapy applications, and led to the notion that gene modification should be avoided when possible. ESC-based therapies could provide a significant control over the factors which have been until now problematic: random insertion sites, allogenic rejection and low numbers of therapeutic cells. Although ESC-based therapies raise a number of unique safety problems, gene modification may play a central role in addressing them. 
